A trial of acceptance and commitment therapy for people with motor neuron disease

Conditions

Motor neuron disease Nervous System Diseases Motor neuron disease

Gould RL, McDermott CJ, Thompson BJ, Rawlinson CV, Bursnall M, Bradburn M, Kumar P, Turton EJ, White DA, Serfaty MA, Graham CD, McCracken LM, Goldstein LH, Al-Chalabi A, Orrell RW, Williams T, Noad R, Baker I, Faull C, Lambert T, Chhetri SK, Ealing J, Hanratty A, Radunovic A, Gunawardana N, Meadows G, Gorrie GH, Young T, Lawrence V, Cooper C, Shaw PJ, Howard RJ, COMMEND Collaboration Group.

2024-05-0917 citations

10.1016/s0140-6736(24)00533-6

Acceptance and Commitment Therapy for people living with motor neuron disease: an uncontrolled feasibility study.

Gould RL, Rawlinson C, Thompson B, Weeks K, Gossage-Worrall R, Cantrill H, Serfaty MA, Graham CD, McCracken LM, White D, Howard RJ, Bursnall M, Bradburn M, Al-Chalabi A, Orrell R, Chhetri SK, Noad R, Radunovic A, Williams T, Young CA, Dick D, Lawrence V, Goldstein LH, Young T, Ealing J, McLeod H, Williams N, Weatherly H, Cave R, Chiwera T, Pagnini F, Cooper C, Shaw PJ, McDermott CJ, and the COMMEND Collaboration Group.

2023-07-076 citations

10.1186/s40814-023-01354-7

The COSI trial: a study protocol for a multi-centre, randomised controlled trial to explore the clinical and cost-effectiveness of the Circle of Security-Parenting Intervention in community perinatal mental health services in England.

Rosan C, Dijk KA, Darwin Z, Babalis D, Cornelius V, Phillips R, Richards L, Wright H, Pilling S, Fearon P, Pizzo E, Fonagy P.

2023-03-144 citations

10.1186/s13063-023-07194-3

A randomised controlled trial of acceptance and commitment therapy plus usual care compared to usual care alone for improving psychological health in people with motor neuron disease (COMMEND): study protocol.

Gould RL, Thompson BJ, Rawlinson C, Kumar P, White D, Serfaty MA, Graham CD, McCracken LM, Bursnall M, Bradburn M, Young T, Howard RJ, Al-Chalabi A, Goldstein LH, Lawrence V, Cooper C, Shaw PJ, McDermott CJ.

2022-11-1510 citations

10.1186/s12883-022-02950-5

Interventions

Phase 1: A manualised intervention will be developed based on Acceptance and Commitment Therapy (ACT) and adapted for people with motor neuron disease (MND). This will be achieved through a series of

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 years and over 2. Diagnosis of familial or sporadic MND (or amyotrophic lateral sclerosis, which is diagnostically synonymous with MND) - diagnosed as definite, laboratory-supported probable or probable according to the World Federation of Neurology’s El Escorial criteria

Exclusion criteria

Exclusion criteria: 1. Need for gastrostomy feeding or non-invasive ventilation (i.e. those in stages 4A or 4B of the King’s College London clinical staging system) 2. Comorbid diagnosis of any form of dementia using standard diagnostic guidelines 3. Already receiving ongoing formal psychological therapy (e.g. Cognitive Behavioural Therapy, psychodynamic psychotherapy, systemic therapy, counselling, etc) at the baseline assessment or unwilling to refrain from engaging in such formal psychological therapy during the receipt of ACT 4. Insufficient understanding of English to enable engagement in the intervention and completion of patient-reported outcome measures 5. Lacking capacity to provide fully informed written consent, verbal consent (for those who cannot provide written consent), or consent via the use of a communication aid 6. Requiring treatment for a severe psychiatric disorder such as schizophrenia, bipolar disorder, or suicidal ideation with active plans/suicidal behaviours and intent 7. For Phase 2 only: Already participated in Phase 1

Design outcomes

Primary

Measure	Time frame
Phase 1: 1. Uptake rate is recorded as the number of eligible participants who consent to participate in the study 2. Initial engagement rate is recorded as the number of eligible participants who complete at least 2 sessions Phase 2: 1. Quality of life is measured using the McGill Quality of Life Questionnaire (Cohen et al., 1995) at baseline, 6 months and 9 months post-randomisation	—

Secondary

Measure	Time frame
Phase 1: 1. Acceptability: 1.1. Satisfaction rate is recorded as the number of eligible participants who consent to participate in the study and give ‘satisfactory’ ratings of therapy using the Satisfaction with Therapy and Therapist Scale-Revised (Oei et al., 2008) at 6 months. There is no set definition of what constitutes “satisfactory” and so this will be defined as a total score of 21 or more on the Satisfaction with Therapy subscale 1.2. Failure to recruit rate due to lack of acceptability is recorded as the number of eligible participants who refuse to consent to participate in the study during the 4-month recruiting period due to lack of acceptability of the intervention 1.3. Attrition rate due to lack of acceptability is recorded as the number of eligible participants who consent to participate in the study that drop out due to lack of acceptability of the intervention by 6 months 2. Feasibility: 2.1. Referral rate is recorded as the number of eligible referrals to the study overall during the 4-month recruiting period 2.2. Failure to recruit rate for reasons other than lack of acceptability is recorded as the number of eligible participants who refuse to consent to participate in the study during the 4-month recruiting period for reasons other than dissatisfaction with therapy 2.3. Attrition rate for reasons other than lack of acceptability is recorded as the number of eligible participants who consent to participate in the study that drop out for reasons other than dissatisfaction with therapy during the 4-month recruiting period 2.4. Deliverability of the intervention within the NHS is recorded as the number of therapy sessions offered (as opposed to completed) during the 3-month therapy period 3. Patient-reported outcome measures: 3.1. Quality of life is measured using the McGill Quality of Life Questionnaire (Cohen et al., 1995) at baseline and 6 months 3.2. Anxiety and depression is measured using the Modified Hospital Anxiety and Depression Scale	—

Measure

Time frame

Phase 1: 1. Acceptability: 1.1. Satisfaction rate is recorded as the number of eligible participants who consent to participate in the study and give ‘satisfactory’ ratings of therapy using the Satisfaction with Therapy and Therapist Scale-Revised (Oei et al., 2008) at 6 months. There is no set definition of what constitutes “satisfactory” and so this will be defined as a total score of 21 or more on the Satisfaction with Therapy subscale 1.2. Failure to recruit rate due to lack of acceptability is recorded as the number of eligible participants who refuse to consent to participate in the study during the 4-month recruiting period due to lack of acceptability of the intervention 1.3. Attrition rate due to lack of acceptability is recorded as the number of eligible participants who consent to participate in the study that drop out due to lack of acceptability of the intervention by 6 months 2. Feasibility: 2.1. Referral rate is recorded as the number of eligible referrals to the study overall during the 4-month recruiting period 2.2. Failure to recruit rate for reasons other than lack of acceptability is recorded as the number of eligible participants who refuse to consent to participate in the study during the 4-month recruiting period for reasons other than dissatisfaction with therapy 2.3. Attrition rate for reasons other than lack of acceptability is recorded as the number of eligible participants who consent to participate in the study that drop out for reasons other than dissatisfaction with therapy during the 4-month recruiting period 2.4. Deliverability of the intervention within the NHS is recorded as the number of therapy sessions offered (as opposed to completed) during the 3-month therapy period 3. Patient-reported outcome measures: 3.1. Quality of life is measured using the McGill Quality of Life Questionnaire (Cohen et al., 1995) at baseline and 6 months 3.2. Anxiety and depression is measured using the Modified Hospital Anxiety and Depression Scale

—

Countries

England, Northern Ireland, Scotland, United Kingdom, Wales

Outcome results

None listed